<DOC>
	<DOCNO>NCT01730378</DOCNO>
	<brief_summary>This study evaluate immunogenicity safety PrepandrixTM Korean subject . A second group subject receive FluarixTM vaccine control .</brief_summary>
	<brief_title>Immunogenicity Safety PrepandrixTM Korean Subjects Aged 18 60 Years Old</brief_title>
	<detailed_description>Initially , 124 subject plan enrol accord 1:1 randomisation ratio . However , mistake , randomisation application set consistent vaccine supply ratio ( 2:1 ) rather treatment group randomization ratio ( 1:1 ) . Subsequently , protocol amend adjust sample size randomisation ratio study . The study enrol 126 subject randomise 2:1 . 84 subject receive Prepandrix™ 42 subject receive Fluarix™ .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol . Or subject investigator believe parent ( ) /Legally Acceptable Representative ( ) comply requirement protocol . Korean male female subject , include , 18 60 year age time first vaccination . Written inform consent obtain subject/ parent ( ) / Legally Acceptable Representative ( ) . Healthy subject free acute aggravation health status establish medical history clinical examination enter study . Access consistent mean telephone contact , may either home workplace , land line mobile , NOT pay phone multipleuser device . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject practice adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period two month completion vaccination series . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . Acute disease and/or fever time enrollment . Subjects minor illness without fever may enrol discretion investigator . Diagnosed cancer , treatment cancer , within past three year . Any confirm suspected immunosuppressive immunodeficient condition , include history human immunodeficiency virus ( HIV ) infection . Family history congenital hereditary immunodeficiency . Any significant disorder coagulation treatment warfarin derivative heparin . Persons receive individual dos low molecular weight heparin outside 24 hour prior vaccination eligible . Persons receive prophylactic antiplatelet medication , e.g. , lowdose aspirin , without clinicallyapparent bleeding tendency , eligible . History neurological disorder seizure . An acute evolve neurological disorder history GuillanBarré syndrome . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Any administration longacting immunemodifying drug within three month study start , plan administration study period . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period . Clinically virologically diagnose influenza infection within six month precede study start . Administration vaccine within 30 day vaccination , plan administration study start . Previous vaccination influenza seasonal pandemic vaccine within six month precede administration study vaccine . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . History allergy reaction likely exacerbate component vaccine , include history severe adverse reaction previous dose influenza vaccine . Female plan become pregnant planning discontinue contraceptive precaution . Child care .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Influenza vaccine</keyword>
</DOC>